Immunosuppression en transplantation rénale: Réalités et perspectives

Medecine Therapeutique

Volumn 2, Issue 3, 1996, Pages 227-234

  Morelon, Emmanuel ^a   Thervet, Éric ^a   Legendre, Christophe ^a  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

15 DEOXYSPERGUALIN; AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN; GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT; LYMPHOCYTE ANTIBODY; MIZORIBINE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; RAPAMYCIN; TACROLIMUS;

DRUG ACTIVITY; DRUG EFFICACY; GRAFT REJECTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; REVIEW; SIGNAL TRANSDUCTION;

EID: 3142583115     PISSN: 12646520     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (28)

1. Scheinman R.I., Cogswell P.C., Lofquist A.K., Baldwin A.S. 1995. Role of transcriptional activation of IkBa in mediation of immunosuppression by glucocorticoids. Science 270: 283-286.
2. Auphan N., DiDonato J.A., Rosette C., Helmberg A., Karin M. 1995. Immunosuppression by glucocorticoids: inhibition of NF-kB activity through induction of IkB synthesis. Science 270 : 286-289.
3. Eugui E.M., Mirkovitch A., Allison A.C. 1991. Lymphocyte-selective antiproliferative and immunosuppressive effects of mycophenolic acid in mice. Scand J Immunol 33 : 175-183.
4. Allison A.C., Kowalski W.J., Muller C J., Walter R.V., Eugui E.M. 1993. Mycophenolic acid and brequinar, inhibitors of purine and pyrimidine synthesis, block the glycosylation of adhesion molecules. Transplant Proc 25 : 67-70.
5. European Mycophenolate Mofetil Cooperative Study Group. 1995. Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. Lancet 345 : 1321-1325.
6. Sollinger H.W., for the US Renal Transplant Mycophenolate Mofetil Study Group. 1995. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. Transplantation 60 : 225-232
7. Bierer B.E., Hollander G., Fruman D. 1993. Cyclosporin A and FK506 : molecular mechanisms of immunosuppression and probes for transplantation biology. Curr Opin Immunol 5 : 763-773.
8. Tocci M.J., et al. 1989. The immunosuppressant FK506 selectively inhibits expression of early T cell activation genes. J Immunol 143 : 718-726.
9. Levy G., Grant D. 1994. Potential for CsA-neoral in organ transplantation. Transplant Pro 26 : 2932-2934.
10. Jordan M.L , et al. 1994. FK506 «rescue» for resistant rejection of renal allografts under primary cyclosporine immunosuppression. Transplantation 57 : 860-865.
11. Shaffer D., Simpson M.A., Conway P., Madras P.M., Monaco A.P. 1995. Normal pancreas allograft function following simultaneous pancreas kidney transplantation after rescue therapy with tacrolimus (FK506). Transplantation 59 : 1063-1065.
12. Shapiro R., et al. 1995. A prospective randomized trial of FK-506-based immunosuppression after renal transplantation. Transplantation 59 : 485-490.
13. Sehgal S.N., Bansbach C.C 1993. Rapamycin : in vitro profile of a new immunosuppressive macrolide. Ann NY Acad Sci 685 : 58-67.
14. Luo H., Chen H., Daloze P., St-Louis G., Wu J. 1993. Anti-CD28 antibody and IL4 induced human T cell proliferation is sensitive to rapamycin. Clin Exp Immunol 94 : 371-376.
15. Kuo C.J , Chung J., Florentino D.F., Flanagan W.M., Blenis J., Crabtree G.R. 1992. Rapamycin selectively inhibits interleukin-2 activation of p70S6 kinase. Nature 358 : 70-73.
16. Ochiai T., Gunji Y., Nagata M., Komori A , Asano T., Isono K. 1993. Effects of rapamycin in experimental organ allografting. Transplantation 56 : 15-19.
17. Yakimets W.J., et al. 1993. Prolongation of canine pancreatic islet allograft survival with combined rapamycin and cyclosporine therapy at low doses. Transplantation 56 : 1293-1298.
18. Thompson A W., Shapiro R., Fung JJ., Starzl T.E. 1993. New immunosuppressive drugs : mechanisms of action and early clinical experience. In : Thompson A.W., Catto G.R D., eds. Immunology of renal transplantation. Londres : Edward Arnold, 264-280.
19. Rebellato L.M., Gross U., Verbenac K.M., Thomas J.M. 1994. A comprehensive definition of the major antibody specificities in polyclonal rabbit antithymocyte globulin. Transplantation 57 : 685-694.
20. Chatenoud L., Baudrihaye M.F., Kreis H., Goldstein G., Schindler J., Bach J.F. 1982. Human in vivo antigenic modulation induced by the anti-T cell OKT3 monoclonal antibody. Eur J Immunol 12 : 979-982.
21. Soulillou J.P., et al. 1990. Randomized controlled trial of a monoclonal antibody against the interleukin-2 receptor (33B3.1) as compared with rabbit antithymocyte globulin for prophylaxis against rejection of renal allografts. N Engl J Med 322: 1175-1182.
22. Arroyo A G., et al. 1994. Induction of tyrosine phosphorylation during ICAM-3 and LFA-1-mediated intercellular adhesion, and its regulation by the CD45 tyrosine phosphatase. J Cell Biol 126 : 1277-1286.
23. Isobe M., Yagita H., Okumura K., Ihara A. 1992. Specific acceptance of cardiac allograft after treatment with antibodies to ICAM-1 and LFA-1. Science 255 : 1125-1127.
24. Fischer A., et al. 1986 Prevention of graft failure by an anti-LFA-1 monoclonal antibody in HLA-mismatched bone marrow transplantation. Lancet 2 : 1058-1061.
25. Le Mauff B., et al. 1991. Effect of anti-LFA1 (CD11a) monoclonal antibodies in acute rejection in human kidney transplantation. Transplantation 52 : 291-296.
26. Hourmant M , et al. 1995. Multicenter study of an anti-LFA1 adhesion molecule monoclonal antibody and anti-thymocyte globulin (ATG) in prophylaxis of acute rejection in kidney transplantation. Chicago: ASTP, Transplant Proc 27 : 864.
27. Lin H., Weil R Q., Gordon D., Linsley P., Turka L.A., Bolling S.F. 1994. Review of CTLA4lg use for allograft immunosuppression. Transplant Proc 26 : 3200-3201.
28. Bromberg J S. 1995. IL1O immunosuppression in transplantation. Curr Opin Immunol 7 : 639-643.